Table 4 Anti-diabetic drugs at baseline and after 6 months by baseline hemoglobin A1c levels (n = 122)
All patients | Baseline hemoglobin A1c (%)* | |||
|---|---|---|---|---|
Group 1 ≤ 7.4% | Group 2 7.5 – 8.9% | Group 3 ≥ 9.0% | ||
n = 122 | n = 55 | n = 41 | n = 26 | |
Baseline (n) | 36 (30%) | 6 (11%) | 25 (61%) | 5 (19%) |
Glibenclamide | 4 (3.45 mg) | 0 | 3 (3.8 mg) | 1 (2.5 mg) |
Gliclazide | 1 (120 mg) | 0 | 1 (120 mg) | 0 |
Glimepiride | 22 (1.84 mg) | 3 (1.5 mg) | 15 (2.0 mg) | 4 (1.5 mg) |
Nateglinide | 3 (120 mg) | 0 | 3 (120 mg) | 0 |
Metformin | 12 (521 mg) | 3 (417 mg) | 8 (531 mg) | 1 (750 mg) |
Pioglitazone | 9 (23 mg) | 4 (23 mg) | 2 (30 mg) | 3 (20 mg) |
Voglibose | 16 (0.6 mg) | 4 (0.7 mg) | 10 (0.6 mg) | 2 (0.9 mg) |
Sitagliptin | 8 (56 mg) | 0 | 7 (57 mg) | 1 (50 mg) |
After 6 months (n) | 17 (14%) | 1 (2%) | 12 (29%) | 4 (15%) |
Glibenclamide | 2 (4.4 mg) | 0 | 1 (7.5 mg) | 1 (1.25 mg) |
Gliclazide | 1 (120 mg) | 0 | 1 (120 mg) | 0 |
Glimepiride | 12 (1.4 mg) | 1 (1.0 mg) | 9 (1.6 mg) | 2 (0.8 mg) |
Nateglinide | 0 | 0 | 0 | 0 |
Metformin | 10 (600 mg) | 0 | 7 (571 mg) | 3 (667 mg) |
Pioglitazone | 1 (30 mg) | 0 | 1 (30 mg) | 0 |
Voglibose | 5 (0.5 mg) | 0 | 5 (0.5 mg) | 0 |
Sitagliptin | 4 (63 mg) | 0 | 4 (63 mg) | 0 |